Progress of therapeutic vaccinations for chronic hepatitis B
10.3760/cma.j.cn501113-20210710-00332
- VernacularTitle:慢性乙型肝炎治疗性疫苗研究进展
- Author:
Ji ZHANG
1
;
Yuzhang WU
Author Information
1. 陆军军医大学全军免疫学研究所，重庆 400038
- Keywords:
Chronic hepatitis B;
Hepatitis B virus;
Therapeutic vaccine;
Immunotherapy;
εPA-44
- From:
Chinese Journal of Hepatology
2021;29(7):631-635
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) causes approximately 30% cirrhosis and 53% liver cancer in the world, and is still a serious threat to human health. Treatment CHB through therapeutic vaccination has long been a urgent goal of the medical community. In the past two decades, various therapeutic vaccines have been developed and studied in clinical trials, however, few has achieved satisfactory results. Recently, a nanoparticle therapeutic vaccine for CHB, εPA-44, has entered pahse III clinical trial. Results of phase II trial for εPA-44 showed that the vaccine had good safety profile and achieved profound clinical benefits in patients with CHB. Here, we first introduce the rational of therapeutic vaccine for CHB and summarize the progress of clinical trials. Finally, we t review the phase II clinical trial data of εPA-44 and discuss the posssible impact to the development of next generation therapeutic vaccine for CHB.
